Blend has been highly productive in generating entirely new classes of platinum drugs as well as other novel molecules with superior therapeutic properties.
Blend’s pipeline includes platinum-based drugs, which are among the most powerful and widely used anticancer therapeutics in use today (see sidebar). Our two lead platinum development programs are:
- new mono-functional platinum molecules with a novel mechanism of action
- new platinum molecules within nanoparticles
In addition, we are applying our proprietary approach to discover and develop other innovative drugs in our pipeline, including:
- additional targeted new molecules with novel modes of action
- combination therapy nanomedicines with optimized therapeutic profiles